Results 1 to 20 of 20
Page 1 of 2
TypeTitleAuthor(s)YearViews
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis BLiaw, Y; Gane, E; Leung, N; Zeuzem, S; Wang, Y; Lai, CL; Heathcote, EJ; Manns, M; Bzowej, N; Niu, J; Han, S; Hwang, SG; Cakaloglu, Y; Tong, MJ; Papatheodoridis, G; Chen, Y; Brown, NA; Albanis, E; Galil, K; Naoumov, NV20091,844
 
The authors replyLai, CL; Gane, E; Brown, NA200857
 
Telbivudine vs Lamivudine in HBeAg-Positive Patients with CHB: Two-Year Efficacy and Predictors of ResponseLai, CL; Gane, E; Hsu, CW; Chen, YC; Thongsawat, S; Wang, Y; Chen, Y; Naoumov, N; Han, SH; Hwang, SG; Lim, SG; Brown, NA2007116
 
Efficacy of telbivudine vs lamivudine at 2 years in patients with hbeag-positive chronic hepatitis B who are eligible for treatment based on guidelinesRasenack, J; Poynard, T; Lai, CL; Gane, E; Brown, NA; Heathcote, J2007137
 
Adefovir salvage therapy for virologic breakthrough in telbivudine-treated patients from the globe studyPane, E; Lai, CL; Min, A; Heathcote, I; Poynard, T; Kurdas, OO; Grange, JD; Brown, NA2007104
 
76 week follow up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switched from adefovir to telbivudineMarcellin, P; Chan, HLY; Lai, CL; Cho, M; Moon, YM; Chao, YC; Heathcote, J; Myers, R; Harb, G; Brown, NA2007118
 
In hepatitis B patients treated with either adefovir or telbivudine, maximal early hbv suppression at 24 weeks predicts optimal one-year efficacyMarcellin, P; Chan, HLY; Lai, CL; Clio, M; Heathcote, I; Moon, YM; Chao, YC; Myers, R; Harb, G; Brown, NA200794
 
Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: A randomized trialChan, HLY; Heathcote, EJ; Marcellin, P; Lai, CL; Cho, M; Moon, YM; Chao, YC; Myers, RP; Minuk, GY; Jeffers, L; Sievert, W; Bzowej, N; Harb, G; Kaiser, R; Qiao, XJ; Brown, NA; Crawford, D; Lim, SG; Chutaputti, A; Poynard, T2007143
 
Telbivudine versus lamivudine in patients with chronic hepatitis BLai, CL; Gane, E; Liaw, YF; Hsu, CW; Thongsawat, S; Wang, Y; Chen, Y; Heathcote, EJ; Rasenack, J; Bzowej, N; Naoumov, NV; Di Bisceglie, AM; Zeuzem, S; Moon, YM; Goodman, Z; Chao, G; Constance, BF; Brown, NA2007256
 
A Randomized Trial of Telbivudine (LdT) vs Adefovir for HBeAg-positive Chronic Hepatitis B: Final Week 52 resultsBzowej, N; Chan, HLY; Lai, CL; Cho, M; Moon, YM; Chao, YC; Heathcote, EJ; Myers, R; Minuk, G; Marcellin, P; Jeffers, L; Sievert, W; Kaiser, R; Harb, G; Chao, GC; Brown, NA2006164
 
Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B PatientsDiBisceglie A, A; Lai, CL; Gane, E; Chen, YC; Thongsawat, S; Wang, YM; Chen, YG; Heathcote, EJ; Zeuzem, S; Rasenack, J; Bzowej, N; Han, SH; Naoumov, N; Hwang, SG; Lim, SG; Chao, GC; Fielman, BA; Brown, NA; Study Group The GLOBE,2006179
 
Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs LamivudineLai, CL; Gane, E; Hsu, CW; Thongsawat, S; Wang, YM; Chen, YG; Heathcote, EJ; Rasenack, J; Bzowej, N; Naoumov, N; Zeuzem, S; Di Bisceglie, A; Chao, GC; Barbara, A; Constance, F; Brown, NA; Study Group The GLOBE.,2006258
 
Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: Pharmacodynamic implicationsZhou, XJ; Lim, SG; Lloyd, DM; Chao, GC; Brown, NA; Lai, CL2006248
 
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis BLai, CL; Leung, N; Teo, EK; Tong, M; Wong, F; Hann, HW; Han, S; Poynard, T; Myers, M; Chao, G; Lloyd, D; Brown, NA20051,180
 
Final results of a phase I/II dose escalation trial of valtorcitabine in patients with chronic hepatitis BLim, SG; Lai, CL; Myers, M; Yuen, RMF; Wai, CT; Lloyd, D; Pietropalolo, K; Zhou, XJ; Chao, G; Brown, NA2005142
 
A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infectionLai, CL; Lim, SG; Brown, NA; Zhou, XJ; Lloyd, DM; Lee, YM; Yuen, MF; Chao, GC; Myers, MW2004120
 
Valtorcitabine provides potent suppression of hepatitis B virus in patients with chronic hepatitis B: Results of a phase I/II clinical trial.Lai, CL; Brown, NA; Yuen, RMF; Wai, CT; Lloyd, D; Pietropaolo, K; Zhou, XJ; Chao, G; Lim, SG2004164
 
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis BPerrillo, RP; Lai, CL; Liaw, YF; Dienstag, JL; Schiff, ER; Schalm, SW; Heathcote, EJenny; Brown, NA; Atkins, M; Woessner, M; Gardner, SD2002111
 
Safe and potent suppression of hepatitis B virus (HBV) with L-deoxythymidine (LDT): Results of a dose-escalation trialLai, CL; Myers, MW; Pow, DM; Brown, NA; Lee, YM; Yuen, RMF; Lim, SG2001128
 
Natural history and lamivudine response in Asians versus Westerners with chronic hepatitis B. (Abstract)Dienstag, JL; Lai, CL; Hann, HWL; Leung, NWY; Grimm, IS; Schiff, E; Woessner, M; Dent, J; Crowther, L; Brown, NA199996
 
Page 1 of 2
Export Records
Step 1: Select content and export format
  • Citation only
Step 2: Select export method
  • Download